ArticleJNCI cancer spectrum2018
Exclusion of Male Patients in Breast Cancer Clinical Trials.
Article in JNCI cancer spectrum, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Trends in male breast cancer in Spain, 1999-2023: a nationwide analysis of incidence and mortality.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- The role of postmastectomy radiotherapy in male breast cancer: a multicenter retrospective study.Frontiers in oncology · 2026Article
- Prior Cancer among Men Diagnosed with Breast Cancer is Associated with Worse Overall Survival but Equivalent Breast Cancer-Specific Survival.Journal of Cancer · 2026Article
- Unraveling the links between estrogen and gut microbiota in sex-hormone driven cancers.World journal of clinical oncology · 2025Review
- Real-world effectiveness of palbociclib plus endocrine therapy in HR+/HER2- advanced breast cancer: final results from the POLARIS trial.The oncologist · 2025Observational
- Redefining therapeutic landscapes: clinicopathological insights into low and ultra-low HER2 expression in male breast cancer.Diagnostic pathology · 2025Article
- Global, Regional, and National Burden of Male Breast Cancer, 1990-2021: A Systematic Analysis for the Global Burden of Disease Study 2021.Cancer medicine · 2025Article
- Male Breast Cancer: Evaluating the Current Landscape of Diagnosis and Treatment.Breast cancer (Dove Medical Press) · 2025Review
- Adjuvant chemotherapy and survival in males aged 70 years or older with breast cancer: a population-based retrospective study.BMC geriatrics · 2024Article
- Male ductal carcinoma in situ: diagnosis and management of a rare disease in men.BMJ case reports · 2024Article
- Male Breast Cancer: a Review on Diagnosis, Treatment, and Survivorship.Current oncology reports · 2024Review
- Breast Cancer in a Filipino Male: A Case Report and Brief Literature Review.Acta medica Philippina · 2024Article
- Revisiting Exclusion of Prior Cancer in Clinical Trials of Male Breast Cancer.Journal of Cancer · 2023Article
- Male triple negative axillary accessory breast cancer-a case report.Translational cancer research · 2022Article
- Genetic Landscape of Male Breast Cancer.Cancers · 2021Review
- Nomogram Predicts the Role of Contralateral Prophylactic Mastectomy in Male Patients With Unilateral Breast Cancer Based on SEER Database: A Competing Risk Analysis.Frontiers in oncology · 2021Article
- Male breast cancer in the United States: Treatment patterns and prognostic factors in the 21st century.Cancer · 2020Article
- Management and outcome of male metastatic breast cancer in the national multicenter observational research program Epidemiological Strategy and Medical Economics (ESME).Therapeutic advances in medical oncology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.